Lactate Dehydrogenase (LDH) as Prognostic Marker in Acute Leukemia Quantitative Method
Walaa Fikry Mohammed Elbossaty*
Department of Chemistry, Faculty of Science, Damietta University, Damietta, Egypt
- Corresponding Author:
- Walaa Fikry Mohammed Elbossaty
Department of Chemistry, Biochemistry division
Faculty of science, Damietta University
Damietta, Box 34517, Egypt
E-mail: [email protected]
Received Date: December 12, 2016; Accepted Date: January 28, 2017; Published Date: February 03, 2017
Citation: Walaa Fikry ME (2017) Lactate Dehydrogenase (LDH) as Prognostic Marker in Acute Leukemia "Quantitative Method". J Blood Disord Transfus 8:375. doi:10.4172/2155-9864.1000375
Copyright: © 2017 Walaa Fikry ME. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Lactate dehydrogenase enzyme was found in animal and human and play important role in gluconeogenesis process. It distributed in all organs, but the mainly distributed in liver. To evaluated the level of lactate dehydrogenase (LDH) in acute leukemia and investigated its clinical significance with other hematological and clinical parameters. Serum lactate dehydrogenase (LDH) level was investigated in 50 patients with acute leukemia, 17 patients with acute lymphoblastic leukemia and 33 patients with acute myeloid leukemia, in addition to 20 healthy control cases. The relationship between lactate dehydrogenase level and blood cells were analyzed. LDH level was significant elevated in acute leukemia cases as compared to control group, also LDH level was statistically significant increase in acute lymphoblastic leukemia than in acute myeloid leukemia (p<0.001). There were positively correlation between LDH and white blood cells, bone marrow blasts and uric acid; on the other hand, there were negatively correlation between LDH and red blood cells, and platelets. Lactate dehydrogenases represented as supplementary enzymatic tool can be used as differentiation marker between the different types of leukemia not only but also, follow up the patients during treatment period.